Skip to main content
SpringerLink
Log in

Antiprotozoenmittel und Anthelminthika

  • Chapter
Pharmakologie und Toxikologie

Part of the book series: Springer-Lehrbuch ((SLB))

  • 42k Accesses

Zusammenfassung

Protozoen und Würmer (Helminthen) spielen in den gemäßigten Breiten nur eine untergeordnete Rolle. In Mitteleuropa vorkommende Protozoen werden durch antibakterielle Chemotherapeutika und Pilzmittel erfasst. Die weltweit wichtigste Protozoenerkrankung ist die Malaria. Sie kann bei Fernreisen erworben werden. Andere tropische Protozoenerkrankungen, z. B. durch Leishmanien und Trypanosomen hervorgerufen, treten aufgrund militärischer und humanitärer Einsätze vermehrt auch in Europa auf. Wurminfestationen rufen vor allem in den Tropen gravierende, chronische Erkrankungen hervor, die unbehandelt die Lebenserwartung deutlich verkürzen. In unseren Breiten sind sie von untergeordneter Bedeutung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Weiterführende Literatur

  • Andrade AL, Martelli CM, Oliveira RM, Silva SA, Aires AI, Soussumi LM, Covas DT, Silva LS, Andrade JG, Travassos LR, Almeida IC (2004) Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 71: 594–597

    CAS  PubMed  Google Scholar 

  • Burri C, Brun R (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 90 Supp 1: S49–52

    Google Scholar 

  • Cardi D, Pozza A, Arnou B, Marchal E, Clausen JD, Andersen JP, Krishna S, Moller JV, le Maire M, Jaxel C (2010) Purified E255L mutant SERCA1a and purified PFATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins. J Biol Chem 285 (34): 26406–26416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ (2008) Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52(8): 2855–2860

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, Fleckenstein L (2013) Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J 12: 70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moore EM, Lockwood DN (2010) Treatment of visceral leishmaniasis. J Glob Infect Dis 2: 151–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis:a multicentre, randomised, phase III, non-inferiority trial. Lancet 374(9683): 5664

    Article  Google Scholar 

  • Singh UK, Prasad R, Mishra OP, Jayswal BP (2006) Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study. Indian J Pediatr 73: 1077–1080

    Article  PubMed  Google Scholar 

  • Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW (2008) New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 47: 1000–1007

    Article  CAS  PubMed  Google Scholar 

  • Supali T, Djuardi Y, Pfarr KM, Wibowo H, Taylor MJ, Hoerauf A, Houwing-Duistermaat JJ, Yazdanbakhsh M, Sartono E (2008) Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 46: 1385–1393

    Article  CAS  PubMed  Google Scholar 

  • Wolstenholme AJ, Rogers AT (2005) Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 131(Suppl): S85–S95

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Physiologie und Pharmakologie, Medizinische Universität Wien, Wien, Österreich

    M. Freissmuth

Authors
  1. M. Freissmuth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Freissmuth, M. (2016). Antiprotozoenmittel und Anthelminthika. In: Pharmakologie und Toxikologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46689-6_60

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-46689-6_60

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-46688-9

  • Online ISBN: 978-3-662-46689-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation